Interesting Tweets from @RNAiAnalyst

Read from bottom

1. Dirk Haussecker ‏@RNAiAnalyst 4h4 hours ago

   $SGMO, however, has IP advantage: 1st mover in a number of Rx areas; plus in ZFN no stepping over each others' toes.

   0 retweets 0 favorites
   

   
   
2. Dirk Haussecker ‏@RNAiAnalyst 4h4 hours ago

   What stuck out is that ZFN/TALEN can do what CRISPR can, but gene k.o. cell line $30-40k vs 1k. does this matter for Rx development? $SGMO

   0 retweets 1 favorite
   

   
   
3. Dirk Haussecker ‏@RNAiAnalyst 4h4 hours ago

   Nice market overview of gene editing in CEN: http://cen.acs.org/articles/93/i35/Genome-Editing-Writ-Large.html … $SGMO

   4h4 hours ago